Drug news
CHMP recommends Vepacel (Baxter) Influenza vaccine
The CHMP has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Vepacel, 7.5 µg Haemagglutinin (HA) antigen per 0.5 ml dose, suspension for injection intended for the prophylaxis of H5N1 subtype of influenza A in either a pre-pandemic or pandemic situation in adults aged 18 years and older. The applicant for this medicinal product is Baxter Innovations GmbH.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins